Targeting fundamentals of inflammation, autoimmunity and fibrosis
Granite Bio Debuts With $100 Million of Capital
–
Granite Bio Debuts With $100 Million of Capital –
Chronic inflammatory diseases represent the most significant cause of death globally. Patients with autoimmune, inflammatory and fibrotic conditions are lacking efficacious treatment options. Granite Bio’s first-in-class assets are designed to target fundamental disease biology.
-
GRT-001
Novel Mode of Action: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP. First-in-class »Innate Rituximab«.
-
GRT-002
Novel Therapeutic Target: Proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and fibrosis.
Two first-in-class therapeutic antibodies GRT-001 and GRT-002
Team:
Granite Bio Team:
-
Patrick Loustau
President and Chief Executive Officer
grey+amolytgrey+bmsgrey+novo -
Dominik Hartl
Chief Medical Officer
grey+roche grey+quell grey+novartis -
Gijs van den Brink
Chief Scientific Officer
grey+rochegrey+gsk grey+forbion -
Kerry Thornton
Executive Assistant
grey+roche grey+vector -
Kerstin Renner
Head Translational Medicine
grey+ukr -
Sofia Forte
Head Clinical Operations
grey+novartis -
Sara Belli
Head Clinical Pharmacology
grey+roche -
Jean-Nicolas Schickel
Head Immunology Discovery
grey+evotecgrey+vectorgrey+sanofi -
Georgios Sarantis
Senior Clinical Trial Manager
grey+novartis grey+pfizer -
Maria Sfichiu
Clinical Trial Manager
grey+sgs grey+idorsia -
Olivia Rudin
Senior Research Associate
grey+cimeio grey+limmatech grey+idorsia -
Hasan-Halit Oz
Senior Scientist Immunology
grey+yale -
Sonia Whitlow
Toxicology Study Monitor
-
Kai Rosport
CMC, Ridgeline Discovery
-
Magali Muller
Biomarker Expert
Remembering:
Giorgio Ferrari
Associate Director ImmunologyGiorgio's career in immunology was both distinguished and impactful. He started his career in Milan in the early 80's, at the Institute of Pharmacology Research ‘’Mario Negri’’, focusing on hematology and immunology in the laboratory of A. Mantovani.
Giorgio contributed significantly to the Immunology field during a decade at the renowned Basel Institute for Immunology, by unveiling key aspects of the immune response to microbial infection, particularly to mycobacteria and pursuing projects on antigen presentation and host-pathogen interaction. Giorgio co-authored multiple works which were published in high-impact factor journals, including "Cell". He later continued his work at the Biozentrum (University Basel) and subsequently at Actelion/Idorsia before joining Granite Bio in June of 2023 as Associate Director in Immunology, where he was a valued colleague and friend.
Beyond his professional achievements, Giorgio will be remembered as a devoted family man and a vibrant presence in the Basel scientific community through his passion, warmth, sociability and his joyful appreciation of life.
Board of Directors:
-
Eliot Forster
Chairman of the Board
-
Patrick Loustau
Granite Bio, President and CEO
grey+amolytgrey+bmsgrey+novo -
Nigel Sheail
Versant Ventures
grey+rochegrey+novartisgrey+versant -
Laia Crespo
Sanofi Ventures
grey+sanofiventures -
Florian Müllershausen
Novartis Venture Fund
grey+nvf -
Markus Enzelberger
Versant Ventures
grey+versant -
Rogier Rooswinkel
Forbion
grey+forbion
Scientific Advisors:
-
Vishwa Deep Dixit
Yale University
Innate Immunity -
Christopher Denton
University College London
Fibrosis -
Jörg Distler
Düsseldorf University
Fibrosis -
Erica Herzog
Yale University
Pulmonary Fibrosis -
Brian Feagan
Ontario, Canada
Inflammatory Bowel Disease -
Florian Rieder
Cleveland Clinic
Inflammatory Bowel Disease -
Scott Brian Snapper
Boston/Harvard University
Inflammatory Bowel Disease -
Carrie Sokol
Boston/Harvard University
Type-II Inflammation
Check out our lastest job posts: